07 Apr Anemocyte
Marco Pupo, Ph.D., Innovation and Development Coordinator
April 29 | 2:30pm | Salone dei Cavalieri, Section 1
Gerenzano,Italy
(Private)
Anemocyte is a leading Italian Biotech Manufacturing Organization (BMO) with extensive experience in the field of Cell and Gene Therapies (CGTs) and nucleic acid research, development and manufacturing. Anemocyte’s core capabilities lie in two specific areas of expertise:
-pDNA (Plasmid DNA);
-mRNA (messenger RNA).The company leverages over twentyfive years of experience to address the continuously evolving needs of the advanced therapies market.
A key innovation differentiating Anemocyte is its proprietary, patent-pending technology, AMCAP™. AMCAP™ is a game-changing one-pot technology for mRNA synthesis that intelligently merges the crucial steps of transcription and capping into a single, seamless reaction resulting in different key advantages such as increase in efficacy and speed, cost-effectiveness, flexibility and scalability. AMCAP™ enables the rapid synthesis of high-performance mRNA, positioning Anemocyte at the forefront of the enzymatic capping evolution in mRNA manufacturing for cell and gene therapies needs.”